COMP <GO>
AORT vs BVS // EV/EBITDA & P/E VALUATION
Artivion Inc. (NYSE) VS. Bioventus Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: AORT 5
— BVS 7
▲ EV/EBITDA & P/E VALUATION LEADER: AORT
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
valuation
19.3x
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
valuation
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. BVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | BVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | 68.30% | -3.90 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | 10.40% | -5.90 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.3x | 26.3x | -7.00 | AORT | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | 5.77% | -5.70 | BVS | /fcf-yield <GO> |
| Operating Margin | 7.60% | 9.50% | -1.90 | BVS | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 4.00% | -1.80 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | -0.90% | +14.50 | AORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | 2.25 | +0.21 | AORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.6 | 43.9 | +2.64 | AORT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | 51.2x | +47.10 | BVS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $1.25B | -$107.6M | BVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | BVS REV | AORT GROSS % | BVS GROSS % | AORT FCF | BVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $568.1M | 64.4% | 68.3% | $839.0K | $72.1M |
| FY 2024 | $388.5M | $573.3M | 64.0% | 67.7% | $11.0M | $37.8M |
| FY 2023 | $354.0M | $512.3M | — | — | $18.8M | $15.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
BVS // BETA —